Organization | Reckitt Benckiser Pharmaceutical

Reckitt Benckiser Pharmaceutical Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Slough United Kingdom (1999)

Status: No NME R&D (1999)

Organization Overview

First Clinical Trial

2005

NCT01075971

First Marketed Drug

1999

dextromethorphan (delsym)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (4)

Key: Reckitt Benckiser Pharmaceutical (3) Acquired (1)

dextromethorphan (delsym) (1982 NDA)

guaifenesin (2002)

norgestrel (Ovral) (2015)

pseudoephedrine (Benylin) (2004)

Drugs in Phase 4 Trials (4)

Key: Reckitt Benckiser Pharmaceutical (1) Acquired (3)

buprenorphine (6 trials)

dextromethorphan (delsym) (1 trial)

guaifenesin (15 trials)

naloxone (narcan) (1 trial)

Drugs in Phase 3 Trials (5)

acetaminophen (tylenol) (2 trials)

calcium alginate (4 trials)

codeine (Phenergan) (1 trial)

flurbiprofen (ansaid) (4 trials)

ibuprofen (motrin) (10 trials)

Drugs in Phase 2 Trials (2)

Key: Reckitt Benckiser Pharmaceutical (1) Acquired (1)

erdosteine (1 trial)

venlafaxine (effexor) (2 trials)

Drugs in Phase 1 Trials (4)

benzydamine (1 trial)

hydrocodone (hycodan) (1 trial)

naproxen (naprosyn) (1 trial)

pseudoephedrine (Benylin) (1 trial)

Indications

Approved Indications

Affect

Cough

Sinusitis

Experimental Indications (Clinical Trials, Phases 1-4)

Common Cold (Phase 4)

Communicable Diseases (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Dyspepsia (Phase 3)

Gastroesophageal Reflux (Phase 3)

Infections (Phase 4)

Opioid-Related Disorders (Phase 3)

Pain, Postoperative (Phase 3)

Pharyngitis (Phase 3)

Respiratory Tract Infections (Phase 4)

Toothache (Phase 3)

Tooth, Impacted (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 42
# of Trial APIs: 15